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Abstract:  Background: Hepatitis B (HBV) vaccination is an important preventive intervention for HIV-infected 
population. Data regarding booster HBV vaccine for persons with low HBV surface antibody (sAb) titers after vaccination 
in this immunocompromised population is lacking. 
Methods: We randomized 60 HIV-infected subjects lacking HBV protection after completion of 3 doses of HBV vaccine 
to receive a booster dose of HBV vaccine with 250mcg GM-CSF as an adjuvant or booster vaccine alone. 
Results: GM-CSF was safe with expected side effects. However, only 35% of persons receiving GM-CSF developed 
protective sAb while 50% in vaccine only arm developed protection (P = 0.47). Overall, only 28% of subjects maintained 
protective sAb 1 year after vaccination. 
Conclusions: GM-CSF failed to improve responses to the booster HBV vaccination. Overall, response was poor with only 
42% of persons responding at one month post-vaccination confirming booster vaccination with the current HBV vaccine 
has poor immunogenicity among HIV-infected persons. Further research is needed to develop optimal vaccination 
strategies in HIV-infected persons. 
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BACKGROUND 
  Hepatitis B virus (HBV), the leading worldwide cause of 
chronic liver disease [1,2], shares routes of transmission with 
Human Immunodeficiency virus (HIV) as manifest by the 
30-90% of HIV-infected patients having evidence of prior 
HBV infection and 10% with chronic infection [3]. In the 
current era of effective antiretroviral therapy (ART), liver 
disease among HIV-infected populations is becoming more 
prominent as AIDS related morbidity and mortality declines 
[4-8]. Current guidelines recommend HBV vaccination for 
all HIV-infected persons who do not have evidence of 
current or past exposure to HBV [9,10]. 
  While vaccination with recombinant HBV vaccine yields 
durable protection in greater than 90% of vaccinated 
immunocompetent adults [11,12], HIV-infected persons 
respond poorly to vaccination with response rates ranging 
from 17 to 56% with standard HBV vaccination strategies 
[13-16]. Therefore, current guidelines for the prevention of 
HBV infection recommend completing a three dose vaccine 
series with double dose vaccine (40mcg) with subsequent 
evaluation of HBsAb titers one month after vaccination and  
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annually to assess durable immunity. In immunocompro-
mised persons such as HIV-infected persons, protective 
immunity persists only while HBsAb >10mIU/mL [17,18]. 
When the antibody level is below this protective level, 
booster vaccination is recommended [19]. 
  Given the poor immunogenicity of HBV vaccine in HIV-
infected persons, several studies have looked at various 
strategies, including booster vaccinations and the use of 
adujvants to boost the immune response. Recombinant 
granulocyte-macrophage colony-stimulating factor (GM-
CSF) is a cytokine produced primarily by activated T and B 
lymphocytes that has been used extensively as a 
hematopoietic growth factor. It increases neutrophil count, 
improves APC function, and is involved in the development 
and perpetuation of cellular immune responses [20]. GM-
CSF has been studied as an adjuvant to HBV vaccination in 
persons with end stage renal disease and HIV-infected 
individuals. A meta-analysis of 13 studies evaluating GM-
CSF as an adjuvant for HBV vaccine yielded a 50% increase 
in the development of seroprotection after a single dose of 
vaccine and a 20% increase after the 3 dose series [21]. 
  We hypothesized that GM-CSF would serve as an 
adjuvant to augment the response to a booster dose of HBV 
vaccine in HIV infected patients who failed the standard 3 
dose HBV vaccine series. This approach has proven effective 
in end stage renal disease patients and dialysis patients, 110    The Open Virology Journal, 2011, Volume 5  Overton et al. 
another group of immunocompromised patients [22-24]. 
This study was developed to evaluate the use of GM-CSF as 
an adjuvant will augment the response to booster vaccination 
in a cohort of HIV-infected persons previously vaccinated 
against HBV. 
METHODS 
  This study was performed at a single site with 60 
participants enrolled. Study participants were HIV-infected 
volunteers without serologic evidence of prior hepatitis B 
infection (negative HBV sAg and negative HBV cAb) and 
who had failed to respond to HBV vaccination, as 
documented by a HBV surface Ab <10 mIU/mL after 
completing the 3 dose HBV vaccination series. Participants 
were required to be >18 years of age and to have a current 
CD4 cell count >100 cells/mL at time of entry. Exclusion 
criteria included current pregnancy, prisoners, other medical 
conditions which may be contraindication for receipt of GM-
CSF, and anticipated inability to complete the requirements 
of the study. 
  The study was approved by the Washington University 
Human Research Protection Office and written informed 
consent was obtained from all study participants prior to 
study initiation. After consent was obtained, participants 
were stratified based on the level of plasma HIV RNA level 
into two groups: those with > 400 copies/mL and those with 
<400 copies/mL. 
  All subjects received a single IM booster dose of 40mcg 
of recombinant HBV vaccine (Recombivax
®) in the deltoid 
muscle. The subjects randomized to the GM-CSF arm then 
received an IM dose of 250mcg of GM-CSF (Leukine
®) 
into the same deltoid muscle. Baseline demographic data as 
well as clinical parameters related to vaccine non-response 
(age, race, gender, BMI, smoking, HCV status) and HIV 
parameters were collected at baseline. 
STUDY ENDPOINTS 
  The primary endpoints in this study were the quantitative 
HBV sAb and the seroconversion rates, defined as HBV sAb 
titer >10 mIU/mL 1 month after vaccination. Secondary 
endpoints included safety and tolerability of the vaccine and 
GM-CSF, changes in CD4 cell count, and plasma HIV viral 
load at 1 month, and quantitative HBsAb at 12 months. 
  Subjects were monitored for 30 minutes after vaccination 
for adverse reactions and then received a phone call at 48 
hours for evaluation of any adverse symptoms. Participants 
returned at day 7 and day 28 for a targeted physical 
examination including vital signs, evaluation of the injection 
site and focusing on any specific signs or symptoms. 
Laboratory evaluation was performed at day 7 and 28 to 
monitor changes in blood counts. Participants returned at 
week 48 for final quantitative HBsAb. 
STATISTICAL ANALYSIS 
  Based on an expected development of HBV sAb > 
10mIU/ml of 60% in the GM-CSF arm and 20% in the 
vaccine only arm, we estimated a sample size of 48. This 
calculation is based on a two-sided  = 0.05 and a  = 0.10. 
Based on an assumed 20% drop-out rate, we enrolled a total 
of 60 participants to the study, 30 participants in each arm. 
 
Differences between groups were determined using 
Student’s t-test for normally distributed continuous 
variables, Mann-Whitney U test for continuous variables not 
normally distributed, and Chi squared test for proportions. 
All analyses were two-tailed and significance was considered 
if the p-value < 0.05. 
RESULTS 
  Sixty HIV-infected subjects, aged 20-60 years (mean age 
37.9 years) were enrolled in the study in 2005 and 2006. The 
majority of the study participants were African American 
(72%) and female (58%). Forty two subjects were on ART at 
study entry with 32 (76%) of those having HV RNA <400 
cp/mL. Other baseline parameters are listed in Table 1. All 
subjects received vaccine or vaccine and GM-CSF and were 
available for initial safety and tolerability assessment. Four 
subjects were found to have reactive HBV cAb at day 7 
assessment and were excluded from subsequent antibody 
evaluation, leaving 27 subjects in the vaccine only arm and 
29 subjects in the vaccine plus GM-CSF arm. Twenty six 
participants in each arm completed the 48 week efficacy 
assessment; in the intervening period, three relocated out of 
the area and one was lost to follow-up. 
IMMUNE RESPONSES 
  Responses to booster vaccination were poor for both 
groups. Overall, only 42% of subjects developed a protective 
antibody response (HBsAb >10mIU/mL). Although there 
was a trend for more responders in the vaccine only arm 
(50% vs 35%), the numbers are small and the results are not 
significant. There was a decrease in antibody responses from 
1 month to 1 year in both arms of the study (28% overall). 
Table  2 shows the immune responses for the two study 
groups. The development of protective Ab response was not 
associated with any of the baseline factors including CD4 
cell count or level of HIV viremia at time of vaccination. 
SAFETY AND SIDE EFFECTS 
  All subjects received a follow-up phone interview at 48 
hours to assess for side effects. Twenty one subjects reported 
at least one side effect, four in the vaccine only arm and 
seventeen in the GM-CSF arm (p <0.001). All side effects 
were mild (grade 1 by the DAIDS toxicity table) and 
resolved within the first 24 hours after vaccination. No 
participant had a side effect requiring bed rest, loss of work, 
or cancellation of social activities. Adverse events are shown 
in Table 3. 
DISCUSSION 
  These data illustrate that GM-CSF is safe with expected 
side effects in HIV-infected subjects when administered as 
an adjuvant for booster HBV vaccination. Unfortunately, in 
this study there was no benefit to giving this adjuvant to 
improve responses in HIV-infected subjects who have failed 
to respond to the initial series of HBV vaccination. 
Furthermore, the use of booster vaccination failed to yield 
protection in a majority of HIV-infected subjects. 
  In immunocompetent persons, protection from HBV 
infection remains intact even when HBsAb titers wane 
<10mIU/mL. Immune memory is preserved and when 
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vaccine), a clonal expansion of memory B and T 
lymphocytes occurs, yielding measurable titers of HbsAb 
and preventing infection [25]. A recent review by Leuridan 
and Van Damme compiled data from 13 published studies 
highlighting a robust anamnestic response to a booster HBV 
vaccine (62-100%) in HIV negative populations [26]. 
Furthermore, Bauer et al. illustrated persistent T and B-cell 
memory in HBV vaccinees with HBsAb titers<10 mIU/mL 
Table 1.  Baseline Demographics and Other Factors 
 
  Vaccine Only (n=30)  Vaccine + GM-CSF (n=30)  p-Value 
Mean Age + SD (in years)  38.5 + 10.0  37.3 + 9.7  0.619 
Race 
AA 
Caucasian 
 
23 (76.7%) 
7 (23.3%) 
 
20 (66.7%) 
10 (33.3%) 
 
0.390 
Gender 
Female 
Male 
 
17 (56.7%) 
13 (43.3%) 
 
18 (60%) 
12 (40%) 
 
0.793 
Mean BMI + SD  29.3 + 7.6  30.3 + 11.1  0.691 
Current smoker  11 (36.7%)  10 (33.3%)  0.787 
Reactive HCV Ab  2 (6.7%)  1 (3.3%)  0.554 
Mean log10 plasma HIV RNA + SD   2.7 + 1.1  3.0 + 1.2  0.455 
Plasma HIV RNA 
< 400 copies/mL 
16 (53.3%)  16 (53.3%)  1.0 
Median Nadir CD4 count (IQR)   162 (71-271)  207 (91-304)  0.429 
Median CD4 count at enrollment (IQR)  375.5 (290-663)  425 (288-564)  0.865 
On ART at enrollment  21 (70%)  21 (70%)  1.0 
 
Table 2.  Immune Responses 
 
  Vaccine Only  Vaccine + GM-CSF  p-Value 
Median 1 month HBsAb 
(range) 
9.4 mIU/mL 
(0->2000) 
0 mIU/mL 
(0->2000) 
NS 
% with HBsAb > 10mIU/mL 
at 1 month 
50% 
(14/28) 
35% 
(10/29) 
0.47 
Median 1 year HBsAb 
(range) 
0 mIU/mL 
(0-1000) 
0 mIU/mL 
(0-258) 
NS 
% with HBsAb > 10mIU/mL 
at 1 year 
33% 
(9/27) 
23% 
(6/26) 
0.71 
 
Table 3.  Adverse Events 
 
  Vaccine Only  Vaccine + GM-CSF  p-Value 
Any adverse event*  4 (13.3%)  17 (56.7%)  <0.001 
Soreness at injection site  0 (0%)  2 (7.7%)  0.150 
Redness at injection site  0 (0%)  0 (0%)  1.0 
Headache  3 (10%)  10 (33.3%)  0.028 
Fever  3 (10%)  8 (26.7%)  0.095 
Chest pain   0 (0%)  2 (7.7%)  0.150 
Dyspnea  1 (3.3%)  1 (3.3%)  1.0 
*Other reported side effects included itching, back pain, leg pain, nausea, dizziness, nasal congestion, and swollen tongue. 
All adverse events were grade 1 and resolved within 24 hours. 112    The Open Virology Journal, 2011, Volume 5  Overton et al. 
suggesting that measurable antibodies are not necessary for 
long term protection [27]. Finally, long term seroprevalence 
studies in high endemic countries report a marked decrease 
in incidence of acute HBV and prevalence of chronic HBV 
carriage since the inception of universal vaccination. Taiwan 
serves as an excellent example where the HBV carrier rate 
has declined from 9.8% before universal vaccination to 0.8% 
23 years after the commencement of the program [28,29]. 
The data from these different types of studies (anamnestic 
responses, residual cellular immunity, and long-term 
epidemiologic studies) have led to the recommendation that 
booster vaccination is not necessary among healthy 
individuals [26,30]. 
  Immunocompromised patients, on the other hand, are at 
risk for HBV infection when HBsAb titer <10mIU/mL. Data 
from dialysis patients and HIV-infected persons illustrate 
that HBsAb titers are significantly lower among 
immunocompromised patients compared to healthy controls 
and that the secondary immune response is not as robust [13-
19, 31]. Additionally, cases of confirmed HBV infection 
(HBsAg reactivity) have been reported among HIV-infected 
persons despite HBV vaccination [32-34]. Therefore, booster 
vaccine is recommended for persons with 
immunocompromised states. Unfortunately, booster vaccine 
generally fails to yield protection in a large proportion of 
subjects. Our findings of 42% response in HIV-infected 
adults are similar to those recently reported in an ACTG 
pediatric study in which 46% of HIV-infected children 
developed protective immunity after a booster dose of HBV 
vaccine [35]. How do we enhance immune responses on 
these at risk populations? 
  Improving the response in immunocompromised patients 
remains challenging. While the initiation of HAART with 
subsequent increase in CD4 cell count and reduction in HIV 
viral load has been associated with improved vaccine 
responses in children and adolescents, the rates of response 
remain below that reported in healthy individuals [35]. The 
utility of alternative strategies, specifically alternative 
adjuvants are one mechanism to augment the response. In 
this study, we elected to evaluate GM-CSF as an adjuvant 
given previous data suggesting its utility for vaccine 
responses in both dialysis patients and HIV-infected persons 
[21-23,36]. Unfortunately, the current study failed to find 
similar benefit with GM-CSF. Rather, the findings are 
similar to results recently published which evaluate the use 
of GM-CSF as an adjuvant for primary HBV vaccine series 
in HIV-infected persons [37]. One question is whether the 
difference in dosing strategies used in these studies accounts 
for the differences in responses reported or if there are 
factors related to the different populations, such as nadir or 
current CD4 cell counts, which may impact response. 
  Nevertheless, these data leave clinicians unclear of the 
appropriate management of vaccine non-responders and 
individuals with waning antibody titers. In HIV-infected 
individuals, the underlying cause for the poor and transient 
response remains intriguing. The altered immune system 
prevents the propagation of an appropriate memory response 
even among those on suppressive ART therapy. Additional 
research is needed to inform the best approach. 
  Our study is limited by a relatively small sample size. It 
is also limited by the fact that we cannot differentiate 
participants who were non-responders to the initial vaccine 
series versus those who responded but had waning HBsAb 
titer. This latter fact may be important as those who initially 
respond may be good candidates for booster vaccination 
rather than require a repeat of the three dose vaccination 
series. The time from receipt of the initial vaccine series and 
the booster dose was highly variable which also may impact 
the response to a booster vaccination. 
  The results from our study confirm that a single booster 
vaccine is unlikely to yield significant immune protection 
against HBV for the HIV-infected population. The 
alternative strategy of repeating the three dose vaccine series 
is an alternative strategy that may yield better results. The 
addition of GM-CSF as an adjuvant, an approach that has 
shown promise in other studies and in other 
immunocompromised populations, failed to improve 
responses in the present study. Continued efforts must strive 
to identify a more effective strategy for HBV vaccination in 
HIV-infected persons. 
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